Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Valeritas Holdings Inc    VLRX

VALERITAS HOLDINGS INC

(VLRX)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Valeritas to Report Fourth Quarter and Full Year 2018 Financial Results on March 5, 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 07:01am EST

BRIDGEWATER, N.J., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced it will release financial results for the fourth quarter and full year 2018 after the close of trading on Tuesday, March 5, 2019.  The company’s management team will host a corresponding conference call beginning at 4:30 PM EST.

Individuals interested in listening to the conference call may do so by dialing (833) 299-8115 for domestic callers or (647) 689-4542 for international callers, using Conference ID: 9876314. To listen to a live webcast, please visit the investor relations section of the Valeritas website at: www.valeritas.com.

About Valeritas Holdings, Inc.

Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with type 2 diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes.  It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.

More information is available at www.valeritas.com and our Twitter feed @Valeritas_US, www.twitter.com/Valeritas_US.

Forward-Looking Statements

This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the V-Go® Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Statements or claims made by third parties regarding the efficacy or functionality of V-Go as compared to other products are statements made by such individual and should not be taken as evidence of clinical trial results supporting such statements or claims. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.  Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at www.sec.gov.

Investor Contacts:
Lynn Pieper Lewis or Greg Chodaczek
Gilmartin Group
646-924-1769
ir@valeritas.com

Media Contact:
Kevin Knight
Knight Marketing Communications, Ltd.
206-451-4823
pr@valeritas.com

valeritas.jpg


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VALERITAS HOLDINGS INC
02/12Valeritas to Report Fourth Quarter and Full Year 2018 Financial Results on Ma..
GL
01/16VALERITAS : Cecelia Health Partners with Valeritas to Support Success of Innovat..
AQ
01/15VALERITAS HOLDINGS INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
01/14VALERITAS : Announces V-Go® Received Preferred Status on OptumRx Formularies
AQ
01/04VALERITAS : Announces V-Go is Preferred on Humana Part D Formularies
AQ
01/03VALERITAS HOLDINGS INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
01/03Valeritas Announces V-Go® is Preferred on Humana Part D Formularies
GL
2018VALERITAS HOLDINGS INC. : Notice of Delisting or Failure to Satisfy a Continued ..
AQ
2018VALERITAS : CEO John Timberlake to Participate as a Panelist on Exploring Innova..
AQ
2018VALERITAS : CEO John Timberlake to Participate as a Panelist on “Exploring..
AQ
More news
Financials ($)
Sales 2018 26,1 M
EBIT 2018 -42,5 M
Net income 2018 -48,5 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 1,50x
Capi. / Sales 2019 1,16x
Capitalization 39,0 M
Chart VALERITAS HOLDINGS INC
Duration : Period :
Valeritas Holdings Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VALERITAS HOLDINGS INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 1,50 $
Spread / Average Target 284%
EPS Revisions
Managers
NameTitle
John E. Timberlake President, Chief Executive Officer & Director
Peter J. Devlin Chairman
Geoffrey H. Jenkins Executive VP-Manufacturing & Operations
Erick J. Lucera Chief Financial Officer, Secretary & Executive VP
Brian K. Roberts Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VALERITAS HOLDINGS INC20.00%39
MEDTRONIC PLC0.30%123 923
BAXTER INTERNATIONAL10.06%39 075
ZIMMER BIOMET HOLDINGS19.22%25 222
HOYA CORPORATION3.55%23 083
TERUMO CORP8.16%22 589